[c09aa8]: / clusters / orderedclusters / clust_289.txt

Download this file

157 lines (156 with data), 5.6 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
Patients may not be receiving any other investigational agents
276.0
Patients receiving any other investigational agents
74.0
Patients receiving any other investigational agents
30.0
Patients who are receiving any other investigational agents
40.0
Patients may not be receiving any other investigational agents
107.0
Patients may not be receiving any other investigational agents
132.0
Patients who are receiving any other investigational agents
24.0
Patients who are receiving any other investigational agents are not eligible
110.0
Patients who are receiving any other anticancer or investigational agents
180.0
Patients should not be receiving any other investigational agents
165.0
Patients receiving any other investigational agents are ineligible
36.0
Patients who are actively receiving any other investigational agents
140.0
Patients should not be receiving any other investigational agents
68.0
Patients should not be receiving any other investigational agents
73.0
Patients may not be receiving any other investigational agents
80.0
Patients receiving any other investigational agents
72.0
Patients may not be receiving any other investigational agents
70.0
Patients who are receiving any other investigational agents
72.0
TUMOR BIOPSY SEQUENCING: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
700.0
TREATMENT: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
700.0
Patients who are receiving any other investigational agents
12.0
Patients who are receiving any other investigational agents
92.0
Patients who are receiving any other investigational agents
100.0
Patients who are receiving any other investigational therapy
40.0
Patients who are receiving any other therapeutic investigational agents
28.0
Patients who are receiving any other investigational agents
24.0
Patients who are receiving any other investigational agents
35.0
Patients receiving any other investigational agents are ineligible
40.0
Receiving any other investigational agents =< 28 days prior to registration
44.0
Patients who are receiving any other investigational agents
57.0
Patients may not be receiving any other investigational agents while on study
NONE
Patients receiving any other investigational agents are ineligible
23.0
Patients who are receiving any other investigational agents
80.0
Patients who are receiving any other investigational agents
37.0
Patients who are receiving any other investigational agents
66.0
Patients who are receiving any other investigational agents
12.0
Participants who are receiving any other investigational agents
42.0
Patients must not currently be receiving any other investigational agents
6452.0
Patients who are receiving any other investigational agents
58.0
Patients who are receiving any other investigational agents
30.0
Patients receiving any other investigational agents are ineligible
75.0
Patients who are receiving any other investigational agents
30.0
Patients may not be receiving any other investigational agents while on study treatment
126.0
Patients who are receiving any other investigational agents
46.0
Patients who are receiving any other investigational agents
35.0
Patients who are receiving any other investigational agents
82.0
Patients who are receiving any other investigational agents
37.0
Patients who are receiving any other investigational agents
50.0
Patients who are receiving any other investigational agents
46.0
Patients who are receiving any other investigational agents
15.0
Patients who are receiving any other investigational agents
46.0
Patients who are receiving any other investigational agents
36.0
Patients who are receiving any other investigational agents
90.0
Patients who are receiving any other investigational agents
45.0
Patients who are receiving any other biologic, cytotoxic or investigational agents
32.0
Participants who are receiving any other investigational agents
18.0
Patients who are receiving any other investigational agents for cancer
60.0
Patients receiving any other investigational agents
64.0
Patients who are receiving any other investigational agents
70.0
Patients who are receiving any other investigational agents
29.0
Patients who are receiving any other investigational agents
51.0
Patients must not be receiving any other investigational anti-cancer agents while on study
714.0
Patients who are receiving any other investigational agents
150.0
Patients who are receiving any other investigational agents
48.0
Patients who are receiving any other investigational agents
20.0
Participants who are receiving any other investigational agents
36.0
Patients who are receiving any other investigational agents
60.0
Patients who are receiving any other investigational agents
38.0
Patients who are receiving any other investigational agents
24.0
Patients who are receiving any other investigational agents
28.0
Patients who are receiving any other investigational agents
30.0
Patients who are receiving any other investigational agents
180.0
Participants who are receiving any other investigational agents
48.0
Patients who are receiving any other investigational agents
132.0
Patients who are receiving any other investigational agents
40.0
Patients who are receiving any other investigational agents
70.0
Patients receiving any other investigational agents are ineligible
30.0
Patients receiving any other investigational agents are ineligible
35.0